05Oct 2024
TNF Inhibitors Reduce Recurrent Cardiovascular Events in Axial Spondyloarthritis

TNF Inhibitors Reduce Recurrent Cardiovascular Events in Axial Spondyloarthritis

This nationwide cohort study evaluated the incidence of recurrent cardiovascular events (myocardial infarction and stroke) in patients with radiographic axial spondyloarthritis (r-axSpA) who had a history of cardiovascular events and assessed the impact of tumor necrosis factor inhibitors (TNFi) on these events. Data from 413 patients were analyzed, revealing an overall incidence rate of 32 per 1,000 person-years. Notably, TNFi exposure was associated with a significantly lower incidence rate of 19 per 1,000 person-years compared to 36 per 1,000 in non-exposed patients. The inverse probability-weighted Cox model indicated that TNFi exposure significantly reduced the risk of recurrent cardiovascular events (hazard ratio 0.33, 95% CI 0.12–0.94). These findings suggest that TNFi may offer protective benefits against recurrent cardiovascular events in r-axSpA patients.

  • #orthopaedics

Like

Save

Share